Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases. Read here
top of page
Recent Posts
See AllJohn Green’s new book Everything is Tuberculosis is scheduled to be published in Spring 2025. The novel laces the experiences of Henry, a...
100
The SIILTIBCY test is now available worldwide through the STOP TB GDF for $1.50 per dose. This novel testing option provides an...
80
The WHO has released the 2024 Global Tuberculosis Report and it places TB as the leading infectious disease killer, surpassing COVID-19....
140
bottom of page
留言